{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:55:38Z","timestamp":1780563338385,"version":"3.54.1"},"reference-count":53,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000294","name":"Medical Research Scotland","doi-asserted-by":"publisher","award":["VAC-1437-2019"],"award-info":[{"award-number":["VAC-1437-2019"]}],"id":[{"id":"10.13039\/501100000294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Pain"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There are concerns about rising drug-related deaths and the potential contribution of prescription analgesics. There is limited understanding regarding the role of prescription analgesics in non-fatal overdoses (NFODs), nor is there a good understanding of what factors are associated with more severe overdose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore risk factors and characteristics of NFODs among people attending a specialist community-based substance misuse service.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After Caldicott approval, data on NFODs, in people attending the Tayside Substance Misuse Service (TSMS), were extracted from the Scottish Ambulance Service database, along with opioid replacement therapy (ORT) prescribing data. Statistical analysis was performed using R studio and Microsoft Excel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>557 people (78% [434\/556] male, mean age \u00b1 standard deviation 38.4 \u00b1 7.95) had an NFOD. Repeat NFODs were more likely in males compared to females ( p &lt; .0065). Males were more likely to be administered naloxone (OR = 1.94, 95% CI = 1.10\u20133.40, p &lt; .02). NFODs at home were more likely to be moderate to severe (categorized by Glasgow Comma Scale [ p &lt; .02, OR = 4.95, 95% CI = 1.24\u201324.38]). Methadone (321\/557, 57.63%), benzodiazepines (281\/557, 50.45%) and heroin (244\/557, 43.81%) were the commonest substances: prescribed methadone overdose was more likely than buprenorphine ( p &lt; .00001). Opioids and benzodiazepines were often taken together (275\/557, 49.40%), with almost all gabapentinoid NFODs also involving opioids (60\/61, 98.40%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Polysubstance use with opioids prescribed for ORT, such as methadone, is highly likely to be implicated in NFOD, with males being at the highest risk of severe and repeat NFOD. Future work should focus on strategies to further reduce NFODs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20494637221095447","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T10:01:34Z","timestamp":1653386494000},"page":"458-466","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics of non-fatal overdoses and associated risk factors in patients attending a specialist community-based substance misuse service"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-7040","authenticated-orcid":false,"given":"Riya","family":"Ghose","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cowden","sequence":"additional","affiliation":[{"name":"Tayside Substance Misuse Service, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abirami","family":"Veluchamy","sequence":"additional","affiliation":[{"name":"Department of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair H","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Medical Research Institute, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A","family":"Colvin","sequence":"additional","affiliation":[{"name":"Department of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"bibr1-20494637221095447","unstructured":"Drug Deaths in Tayside. Scotland 2017 annual report tayside drug death review group, https:\/\/www.nhstaysidecdn.scot.nhs.uk\/NHSTaysideWeb\/idcplg?IdcService=GET_SECURE_FILE&Rendition=web&RevisionSelectionMethod=LatestReleased&noSaveAs=1&dDocName=prod_310127 (accessed 10 July 2019)"},{"key":"bibr2-20494637221095447","unstructured":"Scottish Government. Crime and justice assessing the scale and impact of illicit drug markets in Scotland, https:\/\/www.gov.scot\/binaries\/content\/documents\/govscot\/publications\/statistics\/2021\/02\/assessing-the-scale-and-impact-of-illicit-drug-markets-in-scotland\/documents\/assessing-the-scale-and-impact-of-illicit-drug-markets-in-scotland\/assessing-the-scale-and (2009, accessed 10 July 2019)."},{"key":"bibr3-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2015.05.016"},{"key":"bibr4-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.05031.x"},{"key":"bibr5-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010364"},{"key":"bibr6-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1507771"},{"key":"bibr7-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2018.02.022"},{"key":"bibr8-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"bibr9-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.05.017"},{"key":"bibr10-20494637221095447","unstructured":"NICE. Neuropathic pain in adults: pharmacological management in non-specialist settings, https:\/\/www.nice.org.uk\/guidance\/CG173\/chapter\/1-Recommendations#key-principles-of-care (accessed 4 March 2021)."},{"key":"bibr11-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1159\/000355268"},{"key":"bibr12-20494637221095447","unstructured":"Hypnotics and anxiolytics | Treatment summary | BNF content published by NICE [Internet], https:\/\/bnf.nice.org.uk\/treatment-summary\/hypnotics-and-anxiolytics.html (accessed 10 July 2019)."},{"key":"bibr13-20494637221095447","unstructured":"Johnson CF, Barnsdale LR, McAuley A. Investigating the role of benzodiazepines in drug-related mortality, https:\/\/www.scotpho.org.uk\/media\/1159\/scotpho160209-investigating-the-role-of-benzodiazepines-in-drug-related-mortality.pdf (accessed 7 March 2021)."},{"key":"bibr14-20494637221095447","unstructured":"Barnsdale L. Information services division an official statistics publication for scotland the national drug-related deaths database (Scotland) report, https:\/\/www.isdscotland.org\/Health-Topics\/Drugs-and-Alcohol-Misuse\/Publications\/2018-06-12\/2018-06-12-NDRDD-Report.pdf (accessed 7 March 2021)"},{"key":"bibr15-20494637221095447","unstructured":"Records of Scotland. Drug-related deaths in Scotland in 2020, report, https:\/\/www.nrscotland.gov.uk\/files\/\/statistics\/drug-related-deaths\/20\/drug-related-deaths-20-pub.pdf (2021, accessed 11 August 2021)."},{"key":"bibr16-20494637221095447","unstructured":"Drug Deaths in Tayside. Scotland 2019 annual report, https:\/\/www.nhstaysidecdn.scot.nhs.uk\/NHSTaysideWeb\/idcplg?IdcService=GET_SECURE_FILE&dDocName=PROD_346038&Rendition=web&RevisionSelectionMethod=LatestReleased&noSaveAs=1 (accessed 1 June 2021)."},{"key":"bibr17-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.02.024"},{"key":"bibr18-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-105"},{"key":"bibr19-20494637221095447","unstructured":"Scottish Index of Multiple Deprivation 2020 - gov.scot, https:\/\/www.gov.scot\/collections\/scottish-index-of-multiple-deprivation-2020\/ (accessed 6 March 2021)."},{"key":"bibr20-20494637221095447","unstructured":"NHS National Services Scotland. Scottish index of multiple deprivation - NSS, https:\/\/nhsnss.org\/services\/practitioner\/dental\/scottish-index-of-multiple-deprivation-simd\/ (accessed 6 March 2021)."},{"key":"bibr21-20494637221095447","unstructured":"Microsoft Corporation, https:\/\/office.microsoft.com\/excel"},{"key":"bibr22-20494637221095447","unstructured":"R Core Team, https:\/\/www.r-project.org\/"},{"key":"bibr23-20494637221095447","unstructured":"NHS. Reversal of opioid-induced respiratory depression, https:\/\/handbook.ggcmedicines.org.uk\/guidelines\/drug-overdose-and-toxicity\/reversal-of-opioid-induced-respiratory-depression\/ (accessed 19 July 2019)."},{"key":"bibr24-20494637221095447","unstructured":"BrainLine. What is the glasgow coma scale? https:\/\/www.brainline.org\/article\/what-glasgow-coma-scale (accessed 28 July 2019)."},{"key":"bibr25-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011224"},{"key":"bibr26-20494637221095447","unstructured":"Scottish Government. Crime and justice reducing drug users\u2019 risk of overdose, https:\/\/lx.iriss.org.uk\/sites\/default\/files\/resources\/Reducingdrugusers%27.pdf (2008, accessed 7 March 2021)."},{"key":"bibr27-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2008.07.002"},{"key":"bibr28-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-017-0422-8"},{"key":"bibr29-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.05.022"},{"key":"bibr30-20494637221095447","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S101700"},{"key":"bibr31-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1097\/JAN.0000000000000230"},{"key":"bibr32-20494637221095447","unstructured":"Faculty of Pain Medicine. Substance misuse: chronic pain management, https:\/\/fpm.ac.uk\/opioids-aware-opioids-addiction\/substance-misuse-chronic-pain-management (accessed 13 August 2021)."},{"key":"bibr33-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1093\/jurban\/jtg030"},{"key":"bibr34-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00057.x"},{"key":"bibr35-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1111\/padr.12336"},{"key":"bibr36-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31203-0"},{"key":"bibr37-20494637221095447","doi-asserted-by":"publisher","DOI":"10.3109\/10903127.2015.1076096"},{"issue":"1","key":"bibr38-20494637221095447","first-page":"55","volume":"29","author":"Green CA","year":"2006","journal-title":"Alcohol Res Health"},{"key":"bibr39-20494637221095447","unstructured":"CDC Injury Center. Drug overdose: understanding the epidemic, https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html (accessed 12 March 2022)."},{"key":"bibr40-20494637221095447","unstructured":"NCBI. Trends in opioid use, harms, and treatment - pain management and the opioid epidemic - NCBI Bookshelf, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK458661\/ (accessed 12 March 2022)."},{"key":"bibr41-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36687"},{"key":"bibr42-20494637221095447","unstructured":"NICE. 1 Guidance: Methadone and buprenorphine for the management of opioid dependence, https:\/\/www.nice.org.uk\/guidance\/TA114\/chapter\/1-Guidance (accessed 20 July 2019)."},{"key":"bibr43-20494637221095447","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022030-00002"},{"key":"bibr44-20494637221095447","unstructured":"Department of Health and Social Care. Drug misuse and dependence UK guidelines on clinical management, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf (accessed 7 March 2021)."},{"key":"bibr45-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"bibr46-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1111\/add.14114"},{"key":"bibr47-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1111\/add.14188"},{"key":"bibr48-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.02025.x"},{"key":"bibr49-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5475"},{"key":"bibr50-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.09.007"},{"key":"bibr51-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.07.005"},{"key":"bibr52-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-019-02871-9"},{"key":"bibr53-20494637221095447","doi-asserted-by":"publisher","DOI":"10.1080\/24734306.2019.1700339"}],"container-title":["British Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20494637221095447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20494637221095447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20494637221095447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:21:37Z","timestamp":1777382497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20494637221095447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/20494637221095447"],"URL":"https:\/\/doi.org\/10.1177\/20494637221095447","relation":{},"ISSN":["2049-4637","2049-4645"],"issn-type":[{"value":"2049-4637","type":"print"},{"value":"2049-4645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}